Nucleoside News and Research

RSS

Study shows how many HBeAg-negative patients can achieve permanent immune control of hepatitis B

More than half of patients who suffer from chronic hepatitis B have the e antigen (HBeAg)-negative form of the disease.

30 Mar 2023

New compound limits the replication of influenza viruses

Viruses use the molecular repertoire of the host cell to replicate. Researchers from the Cluster of Excellence ImmunoSensation2 at the University of Bonn, together with Japanese researchers, want to exploit this for the treatment of influenza.

9 Feb 2023

Researchers review the association between endogenous retrovirus reactivation and aging

Researchers explored the role of endogenous retrovirus (ERV) reactivation in the aging process.

24 Jan 2023

Does the immunization order of vaccine types influence the efficacy of heterologous prime-boost vaccination, especially mRNA and protein-based vaccines?

A new study aimed to analyze whether the order of immunization of vaccine types impacted the efficacy of a heterologous prime-boost vaccination strategy.

6 Jan 2023

Newly designed antibiotic effective against multidrug-resistant bacteria

Researchers have designed and synthesized analogs of a new antibiotic that is effective against multidrug-resistant bacteria, opening a new front in the fight against these infections.

20 Dec 2022

New approach may serve as the basis for universal flu vaccines

Claudia Arevalo and colleagues have developed a mRNA lipid nanoparticle vaccine that contains antigens from all 20 known subtypes of influenza A and B viruses, a strategy that may serve as the basis for universal flu vaccines.

24 Nov 2022

What are the current challenges and future directions of mRNA nanomedicine?

Researchers presented challenges related to the clinical translation of messenger ribonucleic acid (mRNA) technology, recent innovations and future directions to improve the clinical efficacy of mRNA nanomedicine.

15 Nov 2022

Exploring antiviral drug combinations for SARS-CoV-2 suppression

Researchers assessed the impact of drug combinations on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) suppression.

14 Nov 2022

How mRNA vaccines work without an added adjuvant

In a recent study published in the Immunity journal, researchers explored the current knowledge of the mechanism employed by messenger ribonucleic acid (mRNA) vaccines to elicit innate immune activation.

13 Nov 2022

Empty lipid nanoparticles trigger maturation and activation of antigen-presenting cells

In a recent study posted to the Research Square* preprint server and under review at the Nature Portfolio journal, researchers reported activation and maturation of antigen-presenting cells (APCs) by lipid nanoparticles (LNPs).

9 Nov 2022

The impact of seasonal coronavirus immunity on susceptibility to SARS-CoV-2 infection and COVID-19 vaccination

Researchers investigated whether immunity against seasonal human coronavirus spike proteins of HKU1, OC43, NL63, or 229E could protect against SARS-CoV-2 in vitro.

28 Oct 2022

Rare insect-eating mushrooms show potential to develop new anti-viral and cancer medications

Scientists studying the medicinal potential of a rare insect-eating mushroom have found a way to grow the elusive fungi in the lab, opening the way for the development of new anti-viral and cancer medications.

19 Oct 2022

Study reviews hydroxychloroquine and remdesivir antiviral potency against SARS‐CoV‐2

In a new study, researchers outlined the synthesis and the possible mechanism of action (MOA) of two potential severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) repurposing drug candidates.

17 Oct 2022

Inhalation therapeutics against COVID-19

A recent study published in the Pulmonary Pharmacology & Therapeutics journal described different inhalation therapeutic agents for treating respiratory viral infections like coronavirus disease 2019 (COVID-19).

17 Oct 2022

Researchers explore drug-repurposing candidates acting against nucleotide-binding pockets of multiple SARS-CoV-2 proteins

In a new study, researchers pursued direct-acting severe acute respiratory syndrome coronavirus-2 drugs that compete for nucleotide-binding pockets (NBPs) of SARS-CoV-2 proteins.

11 Oct 2022

Nucleoside News and Research

Study shows how many HBeAg-negative patients can achieve permanent immune control of hepatitis B

New compound limits the replication of influenza viruses

Researchers review the association between endogenous retrovirus reactivation and aging

Does the immunization order of vaccine types influence the efficacy of heterologous prime-boost vaccination, especially mRNA and protein-based vaccines?

Newly designed antibiotic effective against multidrug-resistant bacteria

New approach may serve as the basis for universal flu vaccines

What are the current challenges and future directions of mRNA nanomedicine?

Exploring antiviral drug combinations for SARS-CoV-2 suppression

How mRNA vaccines work without an added adjuvant

Empty lipid nanoparticles trigger maturation and activation of antigen-presenting cells

The impact of seasonal coronavirus immunity on susceptibility to SARS-CoV-2 infection and COVID-19 vaccination

Rare insect-eating mushrooms show potential to develop new anti-viral and cancer medications

Study reviews hydroxychloroquine and remdesivir antiviral potency against SARS‐CoV‐2

Inhalation therapeutics against COVID-19

Researchers explore drug-repurposing candidates acting against nucleotide-binding pockets of multiple SARS-CoV-2 proteins

Are men or women impacted more by adverse reactions to prescription drug treatments?

RNA-dependent RNA polymerase inhibitors in COVID-19 therapy

Chronic liver disease in COVID-19 patients

Exploring remdesivir resistance in COVID-19-infected transplant recipients

Virology of the human monkeypox virus

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News